Sanofi Company Profile (NYSE:SNY)

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: NYSE:SNY
  • CUSIP: N/A
  • Web:
  • Market Cap: $126.14705 billion
  • Outstanding Shares: 2,525,475,000
Average Prices:
  • 50 Day Moving Avg: $48.82
  • 200 Day Moving Avg: $44.16
  • 52 Week Range: $36.81 - $50.24
  • Trailing P/E Ratio: 12.17
  • Foreward P/E Ratio: 14.94
  • P/E Growth: 1.61
Sales & Book Value:
  • Annual Revenue: $39.98 billion
  • Price / Sales: 3.11
  • Book Value: $25.35 per share
  • Price / Book: 1.94
  • Annual Dividend: $1.10
  • Dividend Yield: 2.2%
  • EBIDTA: $11.8 billion
  • Net Margins: 26.55%
  • Return on Equity: 25.89%
  • Return on Assets: 14.24%
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.20%
  • Average Volume: 1.81 million shs.
  • Beta: 0.93
  • Short Ratio: 1.89

Frequently Asked Questions for Sanofi (NYSE:SNY)

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi declared an annual dividend on Friday, February 17th. Stockholders of record on Monday, May 15th will be given a dividend of $1.5771 per share on Wednesday, June 7th. This represents a dividend yield of 3.65%. The ex-dividend date of this dividend is Thursday, May 11th. This is a positive change from Sanofi's previous annual dividend of $1.10. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi (NYSE:SNY) issued its quarterly earnings results on Friday, April, 28th. The company reported $0.76 EPS for the quarter, beating the Zacks' consensus estimate of $0.73 by $0.03. The business had revenue of $8.65 billion for the quarter, compared to the consensus estimate of $8.40 billion. Sanofi had a return on equity of 25.89% and a net margin of 26.55%. The company's revenue was up 1.2% on a year-over-year basis. View Sanofi's Earnings History.

Where is Sanofi's stock going? Where will Sanofi's stock price be in 2017?

14 equities research analysts have issued 1 year price targets for Sanofi's shares. Their predictions range from $55.00 to $93.00. On average, they anticipate Sanofi's stock price to reach $74.00 in the next twelve months. View Analyst Ratings for Sanofi.

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team

Who owns Sanofi stock?

Sanofi's stock is owned by many different of retail and institutional investors. Top institutional investors include Barrow Hanley Mewhinney & Strauss LLC (1.16%), Fisher Asset Management LLC (0.50%), Hotchkis & Wiley Capital Management LLC (0.41%), Boston Partners (0.34%), Bank of America Corp DE (0.30%) and FMR LLC (0.21%). View Institutional Ownership Trends for Sanofi.

Who sold Sanofi stock? Who is selling Sanofi stock?

Sanofi's stock was sold by a variety of institutional investors in the last quarter, including Hotchkis & Wiley Capital Management LLC, Morgan Stanley, Baird Financial Group Inc., SG Americas Securities LLC, FMR LLC, Jane Street Group LLC, Boston Partners and Paulson & CO. Inc.. View Insider Buying and Selling for Sanofi.

Who bought Sanofi stock? Who is buying Sanofi stock?

Sanofi's stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Global Financial Private Capital LLC, Karp Capital Management Corp, Bank of America Corp DE, Russell Investments Group Ltd., Mondrian Investment Partners LTD, Parametric Portfolio Associates LLC and Hamlin Capital Management LLC. View Insider Buying and Selling for Sanofi.

How do I buy Sanofi stock?

Shares of Sanofi can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of Sanofi stock can currently be purchased for approximately $49.29.

MarketBeat Community Rating for Sanofi (NYSE SNY)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  417
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi (NYSE:SNY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 8 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: $74.00 (50.13% upside)

Analysts' Ratings History for Sanofi (NYSE:SNY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/9/2017ArgusBoost Price TargetBuy$50.00 -> $55.00LowView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
4/20/2017J P Morgan Chase & CoReiterated RatingNeutralMediumView Rating Details
4/7/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageHold -> HoldLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageUnderweightN/AView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingHoldN/AView Rating Details
11/29/2016Morgan StanleyUpgradeEqual Weight -> OverweightN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies Group LLCReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016Citigroup Inc.Reiterated RatingNeutralN/AView Rating Details
5/3/2016Bank of America CorporationReiterated RatingBuy$58.00N/AView Rating Details
4/12/2016Chardan CapitalReiterated RatingBuyN/AView Rating Details
2/10/2016Sanford C. BernsteinLower Price TargetMarket-Perform$52.00 -> $45.00N/AView Rating Details
12/16/2015Oddo SecuritiesDowngradeReduceN/AView Rating Details
11/9/2015Bryan, Garnier & CoReiterated RatingBuy -> NeutralN/AView Rating Details
9/16/2015Sarasin & PartnersUpgradeBuyN/AView Rating Details
7/13/2015Deutsche Bank AGUpgradeBuyN/AView Rating Details
(Data available from 6/28/2015 forward)


Earnings History for Sanofi (NYSE:SNY)
Earnings by Quarter for Sanofi (NYSE:SNY)
Earnings History by Quarter for Sanofi (NYSE SNY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/20173/31/2017$0.73$0.76$8.40 billion$8.65 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.88 billionViewN/AView Earnings Details
10/29/2015Q315$0.88$0.89$10.97 billion$10.67 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.21 billion$9.78 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.34 billion$10.39 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.19 billion$10.82 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.19 billion$10.88 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93ViewN/AView Earnings Details
10/30/2013$1.01$0.93ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sanofi (NYSE:SNY)
2017 EPS Consensus Estimate: $3.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.75$0.78$0.77
Q2 20171$0.74$0.74$0.74
Q3 20171$0.90$0.90$0.90
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)


Current Dividend Information for Sanofi (NYSE:SNY)
Most Recent Dividend:6/7/2017
Annual Dividend:$1.10
Dividend Yield:2.23%
Dividend Growth:-2.50% (3 Year Average)
Payout Ratio:27.64% (Trailing 12 Months of Earnings)
34.59% (Based on This Year's Estimates)
33.33% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Dividend History by Quarter for Sanofi (NYSE SNY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Sanofi (NYSE:SNY)
Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 9.84%
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)
Insider Trades by Quarter for Sanofi (NYSE:SNY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sanofi (NYSE:SNY)
Latest Headlines for Sanofi (NYSE:SNY)
DateHeadline logoAlnylam (ALNY) Sanofi (SNY) Genzyme to Present New Clinical ... - - June 28 at 1:01 AM logoSanofi (SNY) & Regeneron (REGN) Granted EU Marketing Approval from Kevzara (sarilumab) in Combination with ... - - June 28 at 1:01 AM logoAmerican Academy of Family Physicians Foundation Launches Highlight on VACCINATIONS 4 TEENS to Help Address Teen Under-Vaccination - June 27 at 8:00 PM logoSanofi/Regeneron's Kevzara Gets Marketing Approval in EU - June 27 at 8:00 PM logoRegeneron and Sanofi's Kevzara OK'd in Europe for rheumatoid arthritis - June 27 at 8:29 AM logoAlnylam (ALNY) Sanofi (SNY) Genzyme to Present New Clinical Trial Results at ISTH - June 27 at 8:29 AM logo[$$] Third Point Move Could Lead to Nestlé-L’Oréal Decoupling - June 27 at 8:29 AM logoSanofi (SNY) Given Consensus Recommendation of "Hold" by Brokerages - June 26 at 10:02 PM logoSanofi (SNY) Upgraded to Buy by BidaskClub - June 23 at 5:54 PM logoDrugmakers May Lose $390B In Sales Over 5 Years - June 22 at 6:42 PM logoSanofi: Should Value Investors Consider SNY Stock? - Nasdaq - June 21 at 5:40 AM logoSanofi: Should Value Investors Consider SNY Stock? - June 20 at 8:02 AM logoSanofi: A Good Bet On Pharma - Seeking Alpha - June 18 at 11:23 AM logoRegeneron: Coming Up Roses? - June 16 at 1:34 AM logoParexel (PRXL) Enters Collaboration with Sanofi to Advance Wearable Devices in Life Science Industry - June 15 at 3:27 PM logoPAREXEL teams up with Sanofi to advance the use of wearable devices to collect trial data - June 15 at 3:27 PM logoPfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug - June 15 at 3:27 PM logoSanofi: Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan - June 15 at 5:46 AM logoSanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan - June 15 at 1:47 AM logoSanofi all in with biologics production - Reuters - June 14 at 8:18 AM logoSanofi Target of Unusually Large Options Trading (SNY) - June 14 at 7:28 AM logoTech stocks continue their Friday sell-off ahead of this week's Fed meeting - June 13 at 9:48 AM logoFeatured Company News - Data Indicates Sanofi's Soliqua(R) 100/33 Helps in Lowering Hba1c Levels in Type-2 Diabetes Patients - June 13 at 9:48 AM logoForm 4 lululemon athletica inc. For: Jun 08 Filed by: Haselden Stuart - June 12 at 7:24 PM logoRegeneron and Sanofi's Praluent shows significant treatment benefit in diabetics - June 12 at 7:24 PM logoIs the Options Market Predicting a Spike in Sanofi (SNY) Stock? - June 12 at 7:24 PM logoTesaro Stock Jumps on Sanofi, Gilead Takeover Interest - June 12 at 7:24 PM logoGilead and Sanofi eyeing TESARO - StreetInsider - June 12 at 1:02 PM logoSanofi SA (SNY) Downgraded to "Hold" at BidAskClub - June 10 at 12:36 AM logoSanofi SA (SNY) Rating Reiterated by Argus - June 9 at 7:38 PM logoE3 2017: Video Games, Virtual Reality, Entertainment News - June 9 at 9:37 AM logoRegeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue? - June 9 at 9:37 AM logoSanofi-Aventis (SNY) PT Raised to $55 at Argus; 'Strong Demand for MS Drugs... Strong New Drug Pipeline' - - June 8 at 11:54 PM logoSanofi (SNY): Strong Industry, Solid Earnings Estimate Revisions - June 7 at 10:46 AM logoMannKind - Afrezza Scripts Dip As Company Announces Deal For Brazil - June 5 at 9:48 PM logoZacks Investment Research Upgrades Sanofi SA (SNY) to "Buy" - June 2 at 1:50 PM logoSanofi SA (SNY) Receives Average Rating of "Hold" from Analysts - May 30 at 11:04 PM logoSanofi (SNY) Stock Continues to Gain on Key Drug Approvals - May 30 at 7:34 PM logoPerformance of Sanofi Pasteur in 1Q17 - May 30 at 9:01 AM logoPerformance of Sanofi Genzyme in 1Q17 - May 27 at 9:21 PM logoSony Patent Infringement Claim Results in Investigation of FujiFilm Imports - May 27 at 9:21 PM logoSymantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks - May 26 at 7:11 AM logoGardasil and Merck’s Vaccines Business in 1Q17 - May 24 at 9:18 AM logoFDA Approves 1st Drug For GCA, Puma Leaps, Will SBPH Spring A Surprise? - May 23 at 9:14 AM logo​Sanofi Genzyme takes on world’s top-selling drugs with new approval - May 23 at 9:14 AM logoSanofi Wins Favorable CHMP Opinion for Biosimilar Humalog - May 22 at 6:57 PM logoBlog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispro Biosimilar for Treatment of Diabetes Mellitus - May 22 at 8:55 AM logoBull of the Day: Regeneron (REGN) - May 17 at 9:30 AM logoPost Earnings Coverage as Merck's EPS Surged 40%; Raised Outlook - May 15 at 9:14 AM logoHenri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 - May 14 at 11:28 AM



Sanofi (SNY) Chart for Wednesday, June, 28, 2017

This page was last updated on 6/28/2017 by Staff